Characterization of a presymptomatic stage in a Drosophila Parkinson's disease model: Unveiling dopaminergic compensatory mechanisms.

Parkinson's disease (PD) is a degenerative disorder characterized by several motor symptoms including shaking, rigidity, slow movement and difficult walking, which has been associated to the death of nigro-striatal dopaminergic neurons. >90% of PD patients also present olfactory dysfunction. Although the molecular mechanisms responsible for this disease are not clear, hereditary PD is linked to mutations in specific genes, including the PTEN-induced putative kinase 1 (PINK1). In this work we provide for the first time a thorough temporal description of the behavioral effects induced by a mutation in the PINK1 gene in adult Drosophila, a previously described animal model for PD. Our data suggests that the motor deficits associated to PD are fully revealed only by the third week of age. However, olfactory dysfunction is detected as early as the first week of age. We also provide immunofluorescence and neurochemical data that let us propose for the first time the idea that compensatory changes occur in this Drosophila model for PD. These compensatory changes are associated to specific components of the dopaminergic system: the biosynthetic enzymes, Tyrosine hydroxylase and Dopa decarboxylase, and the Dopamine transporter, a plasma membrane protein involved in maintaining dopamine extracellular levels at physiologically relevant levels. Thus, our behavioral, immunofluorescence and neurochemical data help define for the first time presymptomatic and symptomatic phases in this PD animal model, and that compensatory changes occur in the dopaminergic neurons in the presymptomatic stage.

[1]  J. Daigle,et al.  Catecholamines up integrates dopamine synthesis and synaptic trafficking , 2011, Journal of neurochemistry.

[2]  M. Farrer,et al.  Dopamine Transporter Genetic Variants and Pesticides in Parkinson’s Disease , 2009, Environmental health perspectives.

[3]  O. Gershanik Improving l‐dopa therapy: The development of enzyme inhibitors , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  G. Miller,et al.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease , 2017, The European journal of neuroscience.

[5]  J. Calbó,et al.  Neuronal glycogen synthesis contributes to physiological aging , 2014, Aging cell.

[6]  J. Campusano,et al.  Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain , 2004, Brain Research Reviews.

[7]  N. Neff,et al.  Enhancing Aromatic L‐amino Acid Decarboxylase Activity: Implications for L‐DOPA Treatment in Parkinson's Disease , 2008, CNS neuroscience & therapeutics.

[8]  F. Marrosu,et al.  Impaired Sense of Smell in a Drosophila Parkinson’s Model , 2013, PloS one.

[9]  A. Bonnet,et al.  Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. , 2014, Parkinsonism & related disorders.

[10]  R. Klein,et al.  Prevalence of olfactory impairment in older adults. , 2002, JAMA.

[11]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[12]  Bryon Silva,et al.  Serotonin Receptors Expressed in Drosophila Mushroom Bodies Differentially Modulate Larval Locomotion , 2014, PloS one.

[13]  J. Gargano,et al.  Rapid iterative negative geotaxis (RING): a new method for assessing age-related locomotor decline in Drosophila , 2005, Experimental Gerontology.

[14]  R. Varas,et al.  nAChR‐induced octopamine release mediates the effect of nicotine on a startle response in Drosophila melanogaster , 2013, Journal of neurochemistry.

[15]  M. Beal,et al.  Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Neckameyer,et al.  Dopamine and senescence in Drosophila melanogaster ☆ , 2000, Neurobiology of Aging.

[17]  N. Neff,et al.  Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment. , 1990, European journal of pharmacology.

[18]  J. Wessnitzer,et al.  Open Source Tracking and Analysis of Adult Drosophila Locomotion in Buridan's Paradigm with and without Visual Targets , 2012, PloS one.

[19]  D. Nässel,et al.  Aminergic neurons in the brain of blowflies and Drosophila: dopamine- and tyrosine hydroxylase-immunoreactive neurons and their relationship with putative histaminergic neurons , 2004, Cell and Tissue Research.

[20]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[21]  G. Mcclearn,et al.  Differences in locomotor activity across the lifespan of Drosophila melanogaster☆ , 1999, Experimental Gerontology.

[22]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[23]  T. Wright,et al.  The analog inhibitor, α-methyl dopa, as a screening agent for mutants elevating levels of dopa decarboxylase activity in Drosophila melanogaster , 2004, Molecular and General Genetics MGG.

[24]  R. Verleger,et al.  Responsiveness to distracting stimuli, though increased in Parkinson's disease, is decreased in asymptomatic PINK1 and Parkin mutation carriers , 2010, Neuropsychologia.

[25]  L. Nyberg,et al.  The correlative triad among aging, dopamine, and cognition: Current status and future prospects , 2006, Neuroscience & Biobehavioral Reviews.

[26]  D. Mash,et al.  Immunochemical analysis of dopamine transporter protein in Parkinson's disease , 1997, Annals of neurology.

[27]  Christopher Gregg,et al.  Aging Results in Reduced Epidermal Growth Factor Receptor Signaling, Diminished Olfactory Neurogenesis, and Deficits in Fine Olfactory Discrimination , 2004, The Journal of Neuroscience.

[28]  Richard L. Doty,et al.  Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.

[29]  P. Verstreken,et al.  Flies with Parkinson's disease , 2015, Experimental Neurology.

[30]  Sara R. Jones,et al.  Demon Voltammetry and Analysis software: Analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures , 2011, Journal of Neuroscience Methods.

[31]  L. Luo,et al.  A protocol for dissecting Drosophila melanogaster brains for live imaging or immunostaining , 2006, Nature Protocols.

[32]  Christine Klein,et al.  Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes , 2005 .

[33]  R. Varas,et al.  Study of the Contribution of Nicotinic Receptors to the Release of Endogenous Biogenic Amines in Drosophila Brain , 2016 .

[34]  J. Sharma,et al.  Olfactory loss as a supporting feature in the diagnosis of Parkinson’s disease: a pragmatic approach , 2013, Journal of Neurology.

[35]  Li Qian,et al.  Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila , 2006, Proceedings of the National Academy of Sciences.

[36]  J. Brotchie,et al.  Mechanisms compensating for dopamine loss in early Parkinson disease , 2009, Neurology.

[37]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[38]  J. Campusano,et al.  NMDA receptors mediate an early up‐regulation of brain‐derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease , 2009, Journal of neuroscience research.